Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2012. The report details a specific share repurchase transaction executed on October 18, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,000,000 Ordinary Shares of 25 pence each.
- Purchase Date: October 18, 2012.
- Price Range: Highest price paid was 1,428.5 pence per share; lowest price paid was 1,410 pence per share.
- Treasury Holdings (Settled): 507,590,427 shares (9.32% of total issued share capital).
- Treasury Holdings (Including Unsettled): 509,690,427 shares (10.32% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,937,589,064 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,000,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 9.32% of issued capital and 10.32% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total cost of the 1,000,000 share repurchase based on the weighted average price between 1,410 and 1,428.5 pence.
- Confirm the impact of the 10.32% Treasury holding on the denominator for shareholder notification thresholds under Disclosure and Transparency Rules.
- Check subsequent filings to determine if the remaining authorized buyback capacity was utilized.